Document Detail


Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
MedLine Citation:
PMID:  20874675     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which has been proved to be effective in the treatment of pulmonary arterial hypertension (PAH). This review critically addresses and highlights pharmacological aspects of bosentan such as safety, tolerability and drug interactions. The biological basis of its mode of action is demonstrated in preclinical studies on animal models of PH and an up-to-date review of clinical data is provided, supporting its practical use with a view to achieve optimal treatment goals. Major pivotal randomized placebo-control clinical trials are discussed, together with recently published data concerning its promising role as part of combination therapy. Furthermore, recent patents of novel pharmaceutical interventions in the field of PAH, expanding treatment options, are presented.
Authors:
Eva Serasli; Vassilis Michaelidis; Andreas Kosmas; Maria Antoniadou; Venetia Tsara
Related Documents :
12358355 - Genetics of pulmonary hypertension: from bench to bedside.
17715635 - Hepatopulmonary syndrome and portopulmonary hypertension: what's new?
8371225 - Pulmonary capillaritis, alveolar hemorrhage, and recurrent microvascular thrombosis in ...
19168835 - Ct diagnosis of chronic pulmonary thromboembolism.
21082575 - Update on technologies for cardiac valvular replacement, transcatheter innovations, and...
12866145 - Cerebral hemiatrophy: an associated finding in an epileptic child.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Recent patents on cardiovascular drug discovery     Volume:  5     ISSN:  2212-3962     ISO Abbreviation:  Recent Pat Cardiovasc Drug Discov     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-15     Completed Date:  2011-02-22     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  101263805     Medline TA:  Recent Pat Cardiovasc Drug Discov     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  184-95     Citation Subset:  IM    
Affiliation:
2nd Chest Department, G Papanikolaou Hospital, Exohi, Thessaloniki, Greece. serasli@patsialas.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antihypertensive Agents / adverse effects,  pharmacology,  therapeutic use*
Drug Interactions
Humans
Hypertension, Pulmonary / drug therapy*
Randomized Controlled Trials as Topic
Receptors, Endothelin / antagonists & inhibitors*
Sulfonamides / adverse effects,  pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Receptors, Endothelin; 0/Sulfonamides; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Therapeutic medical hypothermia--a multispecialty approach.
Next Document:  Improving red blood cell K-uptake and its impact on O(2)/CO(2) exchange, and NO-generation in microv...